Skip to content
Triangle logo TriangleGet started
← Study library

NCT01242800 · CITED IN SOURCE DOCUMENTS

Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
NA
Status at capture
COMPLETED
Registry last update
2023-06-29

RATIONALE: The primary tumor might be a source of re-seeding of distant sites and therefore elimination of this source of metastasizing cells by early local therapy may be of benefit. PURPOSE: This randomized phase III trial is studying early surgery to see how well it works compared to standard palliative therapy in treating patients with stage IV breast cancer.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

3-year Overall Survival Rate

→

outcome · POSTED

3-year Cumulative Incidence of Locoregional Recurrence/Progression

→

outcome · POSTED

Health-related Quality of Life (HRQL)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Diagnosis of intact primary (not recurrent) invasive carcinoma of the breast * Stage IV disease * Confirmation of the primary tumor should be by needle biopsy (preferred) * Incisional surgical biopsy allowed as long as there is residual palpable or tumor image in the breast * Patients must be judged to be candidates for complete resection with free margins followed by radiation therapy (if radiation therapy is indicated) * For women not undergoing axillary dissection, sentinel node biopsy should document an axillary nodal burden of 1-2 involved lymph nodes (i.e., ACOSOG Z-11 criteria may be applied) * Prior non-invasive (Ductal Carcinoma In Situ) cancer allowed provided there has been no recurrence * Prior ipsilateral invasive cancer allowed if more than 5 years previous * Patients should have at least one organ system involved with distant metastatic disease * If patient has only one metastatic lesion/focus, this must be proven by biopsy and the pathology report confirming the diagnosis of primary breast cancer, as well as the metastatic site, must be available * Must have available radiologic reports documenting disease status within the past 6 weeks prior to initiating systemic therapy * CNS metastases allowed provided projected survival \> 6 months * Patients must have completed at least 16 weeks of optimal systemic therapy (appropriate to the tumor biological profile and the patient's age and menopausal status) * If systemic therapy is discontinued for toxicity, but there is no distant progression and at least 12 weeks of therapy have been delivered, then the patient remains eligible * Radiation therapy (if indicated) must begin within 12 weeks of final therapeutic surgical procedure (including re-excision for free margins and completion of axillary dissection) * Patients may register at any time from the time of diagnosis of stage IV breast cancer (if eligibility criteria met) to the time when a maximum of 30 weeks of induction systemic therapy has been completed * Patients must be randomized within 16-32 weeks after the start of systemic therapy * Patients must not have experienced disease progression since the start of systemic therapy, as evidenced by radiographic documentation of disease status before treatment and within 4 weeks +/- 2 weeks prior to randomization, including: * No new sites of disease * No enlargement of existing sites by 20% or more in longest diameter * No symptomatic deterioration * Patients who require radiotherapy to bone metastases during induction systemic therapy are eligible * Local disease at the primary site must be asymptomatic * Hormone receptor status known * Menopausal status not specified * Patients must have adequate organ function to undergo local therapy 4 weeks +/- 2 weeks prior to randomization per investigator discretion and institutional guidelines * More than 5 years since other primary cancers that were curatively treated * Negative pregnancy test * Fertile patients must use an accepted and effective contraception method Exclusion criteria: * Synchronous contralateral breast cancer * Pregnant or nursing
healthy Volunteers
false
maximum Age
120 Years
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive standard palliative therapy, if needed, to address symptoms such as tumor ulceration, pain, bulky adenopathy causing arm symptoms, and other similar situations. Therapy may consist of radiotherapy alone, surgery alone, or a combination of both.
    intervention Names
    1. Procedure: palliative surgery
    2. Radiation: palliative radiation therapy
    label
    Arm I
    type
    ACTIVE_COMPARATOR
  2. description
    Patients undergo surgery comprising breast-conserving therapy (BCT) or total mastectomy according to patient and treating physician preference. Surgery is to occur no later than 10 weeks after completion of 32 weeks of systemic therapy. Free surgical margins must be achieved with re-excision or mastectomy for patients undergoing BCT. After completion of BCT, patients undergo radiotherapy once a day, 5 days per week. Patients who had mastectomy undergo radiotherapy at the discretion of treating physician.
    intervention Names
    1. Procedure: therapeutic conventional surgery
    2. Radiation: radiation therapy
    label
    Arm II
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Arm I
    description
    Undergo standard palliative surgery
    name
    palliative surgery
    type
    PROCEDURE
  2. arm Group Labels
    1. Arm II
    description
    Undergo early surgery
    name
    therapeutic conventional surgery
    type
    PROCEDURE
  3. arm Group Labels
    1. Arm I
    description
    Undergo standard palliative radiotherapy
    name
    palliative radiation therapy
    type
    RADIATION
  4. arm Group Labels
    1. Arm II
    description
    Undergo radiotherapy
    name
    radiation therapy
    type
    RADIATION
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
390
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Overall survival (OS) was defined as time from randomization to death from any cause. All patients will be followed for survival through 5 years. Cases with incomplete follow-up or without record of vital status will be censored at the date of last contact. 3-year OS rate was estimated using Kaplan-Meier method.
    measure
    3-year Overall Survival Rate
    time Frame
    Assessed at baseline, then every 3 months within 2 years and every 6 months between 2-5 years, up to 5 years
secondary Outcomes
  1. description
    For patients in arm II (early local therapy), time to locoregional recurrence was defined as time from randomization to date of locoregional recurrence; for patients in arm A (continued systemic therapy), time to locoregional progression was defined as time from randomization to date of locoregional progression. In this study, locoregional recurrence was defined as the new development or clinically significant increase in size of any supraclavicular, infraclavicular, internal mammary or axillary adenopathy or chest wall disease or invasive in-breast recurrence for patients on arm B; for patients on arm A, locoregional progression was defined as the development of symptoms leading to a decision for local therapy. Locoregional recurrence/progression and distant progression were followed separately in the study, and the occurrence of one did not preclude the other getting reported. 3-year cumulative incidence of locoregional recurrence/progression was estimated.
    measure
    3-year Cumulative Incidence of Locoregional Recurrence/Progression
    time Frame
    Assessed at baseline, then every 3 months within 2 years and every 6 months between 2-5 years, up to 5 years
  2. description
    The Functional Assessment of Cancer Therapy-Breast Trial Outcome Index (FACT-B TOI) was used as the primary HRQL endpoint, measured by the prorated aggregate score of the 24 items from the FACT-B (7 functional well-being, 7 physical well-being, 10 breast cancer specific items). The theoretical range of the prorated aggregate score was 0-96, higher scores indicate better quality of life.
    measure
    Health-related Quality of Life (HRQL)
    time Frame
    Assessed at 18 months after randomization
Full study description
brief Summary
RATIONALE: The primary tumor might be a source of re-seeding of distant sites and therefore elimination of this source of metastasizing cells by early local therapy may be of benefit. PURPOSE: This randomized phase III trial is studying early surgery to see how well it works compared to standard palliative therapy in treating patients with stage IV breast cancer.
detailed Description
OBJECTIVES: Primary * To evaluate whether early local therapy of intact primary disease in patients with Stage IV breast cancer whose disease does not progress during initial optimal systemic therapy, will result in prolonged survival, compared to patients who receive local therapy for palliation only. Secondary * To compare the time to uncontrolled chest wall disease between patients who receive early local therapy versus patients who receive palliative local therapy. * To determine whether there is a difference in health-related quality-of-life (HRQOL) between patients who receive early local therapy versus patients who receive palliative local therapy. * To determine whether the absolute value of circulating tumor cells (CTC) burden at 6 months following randomization (time +6) will be lower in the palliative therapy arm than in early local therapy arm, and whether this value is inversely related to survival (lower CTC, longer survival). Exploratory * To collect tumor and blood specimens for future exploration of the biological interactions between the primary tumor and metastatic lesions and the effect of primary tumor resection. OUTLINE: This is a multicenter study. Patients are stratified according to hormone receptor and treatment plan (ER+ or PR+, HER2-, endocrine therapy alone vs ER+ or PR+, and HER2-, chemotherapy and/or endocrine therapy vs ER- or PR-, and HER2- vs HER2+), and number of involved organ systems with distant disease (regional nodes in the axillary, supraclavicular, and internal mammary locations are not considered distant sites) (1 vs \> 1). Patients are randomized to 1 of 2 treatment arms in 1:1 ratio. * Arm I: Patients receive standard palliative therapy, if needed, to address symptoms such as tumor ulceration, pain, bulky adenopathy causing arm symptoms, and other similar situations. Therapy may consist of radiotherapy alone, surgery alone, or a combination of both. * Arm II: Patients undergo surgery comprising breast-conserving therapy (BCT) or total mastectomy according to patient and treating physician preference. Surgery is to occur no later than 10 weeks after completion of 32 weeks of systemic therapy. Free surgical margins must be achieved with re-excision or mastectomy for patients undergoing BCT. After completion of BCT, patients undergo radiotherapy once a day, 5 days per week. Patients who had mastectomy undergo radiotherapy at the discretion of treating physician. Patients may undergo blood and tumor tissue sample collection for circulating tumor cells (CTC) burden and future studies. Patients complete the Functional Assessment of Cancer Therapy - Breast Trial Outcome Index (FACT- TOI) and FACT - General (22) and the Breast Cancer Subscale (FACT-B) quality-of-life questionnaires at baseline and periodically during study. After completion of study therapy, patients are followed up periodically for 5 years.
Source references
references
  1. citation
    Khan SA, Zhao F, Goldstein LJ, Cella D, Basik M, Golshan M, Julian TB, Pockaj BA, Lee CA, Razaq W, Sparano JA, Babiera GV, Dy IA, Jain S, Silverman P, Fisher CS, Tevaarwerk AJ, Wagner LI, Sledge GW. Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108). J Clin Oncol. 2022 Mar 20;40(9):978-987. doi: 10.1200/JCO.21.02006. Epub 2022 Jan 7.
    pmid
    34995128
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-3a41f445f02c3dbdc32f
      requested nct id
      NCT01242800
      primary nct id
      NCT01242800
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      862f78faa9e4cbedc19f9ffcaeba97e029ba51b72bb3b81fc67aa8b6adf96904
      payload sha256
      23aa4ad12fba86d156903fe5059dc1c4128379782b21ba417cc961f6b1a1edf1
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-3a41f445f02c3dbdc32f
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT01242800
      occurrences
      1. context exact
        ection id="_1547"> <h3 id="_1547_toc">Surgical Treatment for Metastatic Breast Cancer</h3> <p id="_3603" tabindex="-1">The <a href="/clinicaltrials/NCT01242800">ECOG 2108</a> trial (NCT01242800) evaluated the potential benefit of breast locoregional interventions in patients with metastatic breast cancer. Women prese
        end
        668905
        exact text
        NCT01242800
        start
        668894
      2. context exact
        1547_toc">Surgical Treatment for Metastatic Breast Cancer</h3> <p id="_3603" tabindex="-1">The <a href="/clinicaltrials/NCT01242800">ECOG 2108</a> trial (NCT01242800) evaluated the potential benefit of breast locoregional interventions in patients with metastatic breast cancer. Women presenting with metastatic breast cance
        end
        668939
        exact text
        NCT01242800
        start
        668928
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/29bf1e5a1d739974ed.html
      source file sha256
      862f78faa9e4cbedc19f9ffcaeba97e029ba51b72bb3b81fc67aa8b6adf96904
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:21:35.419733+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      536430925e3b0008edd3fb69a869d5645bd6b6dc5c84c21ddf1b3e24f089874c
      source title
      Breast Cancer Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: April 25, 2025
        datetime
        2025-04-25T12:00:00Z
        display
        April 25, 2025

    Preserved source evidence · Not medical advice